0001209191-20-028898.txt : 20200513
0001209191-20-028898.hdr.sgml : 20200513
20200513172034
ACCESSION NUMBER: 0001209191-20-028898
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200511
FILED AS OF DATE: 20200513
DATE AS OF CHANGE: 20200513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LERNER RICHARD A
CENTRAL INDEX KEY: 0001316274
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 20874246
MAIL ADDRESS:
STREET 1: THE SCRIPPS RESEARCH INSTITUTE
STREET 2: 10550 N. TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-11
0
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001316274
LERNER RICHARD A
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
1
0
0
0
Common Stock
11430
D
Common Stock
2020-05-11
4
M
0
25000
2.74
A
97313
I
Held by the Lerner Family Trust UAD 11/14/94
Common Stock
2020-05-11
4
S
0
3500
20.50
D
93813
I
Held by the Lerner Family Trust UAD 11/14/94
Stock Option (right to buy)
2.74
2020-05-11
4
M
0
12500
0.00
D
2020-06-10
Common Stock
12500
0
D
Stock Option (right to buy)
2.74
2020-05-11
4
M
0
12500
0.00
D
2020-12-21
Common Stock
12500
0
D
Dr. Lerner may be deemed to beneficially own securities held by the Lerner Family Trust UAD 11/14/94 (the "Lerner Family Trust"). Dr. Lerner disclaims beneficial ownership of securities held by the Lerner Family Trust except to the extent of his pecuniary interest therein.
The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the exercise of options.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.51 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
All shares underlying this option have vested.
/s/ Lawrence J. Hineline, Attorney-in-fact
2020-05-13